Swiss National Bank increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 489,200 shares of the biotechnology company’s stock after purchasing an additional 2,300 shares during the period. Swiss National Bank owned 165,354.06% of Exelixis worth $11,853,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in EXEL. Vanguard Group Inc. lifted its holdings in shares of Exelixis by 7.2% in the 2nd quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock worth $626,635,000 after purchasing an additional 1,706,893 shares during the last quarter. Matrix Capital Management Company LP lifted its holdings in shares of Exelixis by 8.8% in the 2nd quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after purchasing an additional 1,225,000 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Exelixis in the 2nd quarter worth approximately $28,689,000. Meditor Group Ltd lifted its holdings in shares of Exelixis by 5.5% in the 2nd quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock worth $498,258,000 after purchasing an additional 1,046,000 shares during the last quarter. Finally, First Trust Advisors LP lifted its holdings in shares of Exelixis by 588.9% in the 3rd quarter. First Trust Advisors LP now owns 1,086,135 shares of the biotechnology company’s stock worth $26,317,000 after purchasing an additional 928,475 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

EXEL has been the topic of several recent research reports. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Tuesday, October 10th. SunTrust Banks, Inc. raised their price target on Exelixis from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, October 16th. Needham & Company LLC raised their price target on Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, October 17th. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Thursday, July 27th. Finally, BidaskClub upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $31.38.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/swiss-national-bank-buys-2300-shares-of-exelixis-inc-exel/1715614.html.

Shares of Exelixis, Inc. (NASDAQ EXEL) opened at $26.38 on Monday. Exelixis, Inc. has a 1 year low of $14.22 and a 1 year high of $32.50. The company has a market capitalization of $7,804.61, a P/E ratio of 51.72, a P/E/G ratio of 1.18 and a beta of 1.89.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company had revenue of $152.50 million for the quarter, compared to analysts’ expectations of $104.91 million. During the same period last year, the firm earned ($0.04) EPS. The firm’s revenue for the quarter was up 145.2% on a year-over-year basis. research analysts forecast that Exelixis, Inc. will post 0.49 EPS for the current year.

In other news, CFO Christopher J. Senner sold 100,000 shares of Exelixis stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total transaction of $2,679,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Jeffrey Hessekiel sold 27,302 shares of Exelixis stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $24.28, for a total value of $662,892.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 970,152 shares of company stock worth $25,923,457. 5.10% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.